| 08.00 | | | Welcome address, Natzi Sakalihasan |
| | | | Distinguished lecture, Frank Lederle |
| | | | |
| | | | | Genetics of aortic diseases
|
| | | | Greg Jones, Matthew Bown
|
| 08.30 | | | Extra-aortic cardiovascular features in Marfan syndrome - Relevance and management, Julie De Backer |
| 08.38 | | | Whole blood DNA methylation analysis in AAA; an epigenome-wide association study, Greg Jones |
| 08.46 | | | Combining Mendelian genetics and genetic epidemiology for AAA, Juliette Albuisson |
| 08.54 | | | New Insights on genetic aspect of aortic disease, John Elefteriades |
| 09.02 | | | Does sex matter in aortic aneurysm and dissection? Bart Loeys |
| 09.10 | | | Genetic risk profile: insights from family based AAA NGS analysis, Danielle Majoor & Arne S Ijpma |
| 09.26 | | | Discussion
|
| | | | Short communications from selected papers
|
| 09.35 | | | • High heritability of abdominal aortic aneurysms – a population-based twinstudy, Trine Maria Mejnert Joergensen |
| 09.40 | | | • Global and gene specific DNA methylation is associated with Abdominal Aortic Aneurysms, Bradley Toghill |
| 09.45 | | | • End-stage human aneurysm disease in different arterial positions is similar – neurysm induction in mouse models however not, Albert Busch |
| 09.50 | | | • Phenotypic switching of SMCs is a potential therapeutic target in popliteal aneurysms, Albert Busch |
| 09.55 | | | • Resveratrol inhibits aortic root dilatation in the Fbn1C1039G/+ Marfan mouse model, Vivian de Waard |
| | | | |
| 10.00
| | | Coffee break
|
| | | | |
| | | | | Epidemiology and treatment of AAA
|
| | | | Frank Lederle, Anders Wanhainen
|
| 10.30 | | | Findings from the Swedish AAA screening program, Anders Wanhainen |
| 10.40
| | | Is risk-factor targeted AAA screening the future? Data from the Oxford Vascular Study, Dominic Howard |
| 10.50
| | | Morphology of ruptured vs unruptured AAA, Janet T. Powell |
| 11.00
| | | AAA rupture in Stockholm, Rebecka Hultgren |
| 11.10
| | | Australian trials to identify treatments to slow AAA growth, Jonathan Golledge |
| 11.20
| | | AAA measurement and enlargement, Frank Lederle |
| 11.30
| | | CT-overestimation of AAA size severely impacts the cost-effectiveness of AAA repair, Jan Lindeman |
| 11.40
| | | Discussion |
| | | | Short communications from selected papers
|
| 12.10 | | | • Immunopathology in patients with AAA, Miroslav Prucha |
| 12.15 | | | • How does it feel to have an abdominal aortic aneurysm – a patient-centered view, Stephanie Tomee |
| 12.20 | | | • Meta-analysis of the current prevalence of screen-detected abdominal aortic aneurysm in women, Pinar Ulug |
| 12.25 | | | • Diameter growth rate and future indication for surgery can be predicted with inite element analysis and semi-automatic diameter measurements in small bdominal aortic aneurysms, Moritz Lindquist Liljeqvist |
| | | | |
| 12.30 | | | Lunch break
|
| | | | |
| | | | | New advances in physiopathology of aortic diseases
|
| | | | Audrey Courtois, Florence Pinet |
| 13.30 | | | Inward neo-angiogenesis in aortic diseases, Jean-Baptiste Michel |
| 13.38 | | | NETosis is associated with abdominal aortic aneurysm rupture, Sean English |
| 13.46 | | | The translational story of the relationship between reversible pulmonary obstructive disease and AAA, Jes Lindholt |
| 13.54 | | | Non-coding RNA and aneurysm, clinical implications: form experimental animal models to therapeutics approaches, Lars Maegdefessel |
| 14.02 | | | Cell-specific expression of non coding RNA in human AAA: new approach to find biomarkers, Florence Pinet |
| 14.10 | | | Circulating miRNA associated with unstable abdominal aortic aneurysm PET positive, Audrey Courtois |
| 14.18 | | | Circulating vascular basement fragments are associated with the diameter of abdominal aorta, Anders Wanhainen |
| 14.26 | | | Discussion
|
| | | | Short communications from selected papers
|
| 14.50 | | | • Transdifferentiation of human dermal fibroblasts to smooth muscle like cells: novel method to study the effect of MYH11 and ACTA2 variants in the aortic neurysm wall, Natalija Bogunovic |
| 14.55 | | | • Live human arterial tissue slices for bench top research on pathophysiology of aortic aneurysms; up to 90 days ex vivo preservation, Jorn Meekel |
| | | | |
| | | | | Generalities on medical treatment of AAA
|
| | | | Gilbert R. Upchurch, Paul Norman
|
| 15.00 | | | Where and why does thrombus develop in aortic disease, Barry Doyle |
| 15.18 | | | Focal adhesion Kinase is a novel target for pharmacotherapy of abdominal aortic aneurysm, Koichi Yoshimura |
| 15.26 | | | Inhibition of aneurysmal progression by local PGG infusion in experimental porcine AAA, Jes Lindholt |
| 15.34 | | | TElmisartan in the management of abDominal aortic aneurYsm (TEDY): the study protocol for a randomized controlled trial, Jonathan Golledge |
| 15.42 | | | What is the role of the KLF4 during the development of abdominal aortic aneurysm, Morgan Salmon |
| 15.50 | | | The effect of metformin on AAA, Ronald Dalman |
| 15.58 | | | What do we know about AAA and diabetes and does it matter? Paul Norman |
| 16.06 | | | Keynote lecture. Medical treatment of the AAA in human. Fiction or reality? Gilbert R. Upchurch |
| 16.14 | | | Discussion
|
| | | | Short communications from selected papers
|
| 16.30 | | | • Inhibition of pathological vascular smooth muscle cell remodelling as a treatment strategy for abdominal aortic aneurysm, Marc Bailey |
| 16.35 | | | • Canonical TGFß-signaling is triggered by inflammtion in human non-syndromic neurysm disease, but is not reflected by inducible AAA mouse models, Albert Busch |
| 16.40 | | | • Phenotyping of transgenic pigs to determine the suitability of xenografts in the treatment of aortic diseases, Ewa Strauss |
| | | | |
| 16.45 | | | Coffee break
|
| | | | |
| | | | | Causes and management of ruptured AAA
|
| | | | Rebecka Hultgren, Ronald Dalman
|
| 17.15 | | | The biology of AAA progression and rupture: beyond MMPs and inflammation, Jan Lindeman |
| 17.23 | | | Imaging alternatives in order to prevent rupture (volume vs diameter), Christian Gasser |
| 17.31 | | | Is the risk different for female or male FDRs to AAA patients? Rebecka Hultgren |
| 17.39 | | | Emergency EVAR – the new standard for almost every patient with a ruptured AAA (technique and own clinical data over 10 years, literature review), Hans-Henning Eckstein |
| 17.47 | | | Open repair of RAAA is always possible - is it always better? Lazar Davidovic |
| 17.55 | | | Prolonged or renewed ICU stay after AAA-repair - a “crash investigation”, Anders Wanhainen |
| 18.03 | | | TAVI, MAVI, TEVAR, EVAR - The end of standard cardiovascular surgery? Perspectives of a cardiac surgeon, Daniel Fink |
| 18.11 | | | Staged hybrid repair of extensive TAAA, Gilbert R. Upchurch |
| 18.19 | | | Keynote lecture. Lessons learned from IMPROVE trial, Janet T. Powell |
| 18.27 | | | Questions to experts & panel discussion |
| | | | Short communications from selected papers
|
| 18.40 | | | • Management of visceral artery aneurysms: a 20-year single centre experience, Gianfranco Filippone |
| 18.45 | | | • Aortic size index could improve surveillance of women and men with AAA, Rebecka Hultgren |
| 18.50 | | | • How common is the classic triad of symptoms in patients with ruptured AAA? Rebecka Hultgren |
| 18.55 | | | • Survival disparity following AAA repair highlights inequality in socioeconomic status, Manar Khashram |
| 19.00 | | | • Patient reported quality and functional life after AAA repair, Manar Khashram |
| | | | |
| | | | |
| 19.05 | | | End of the sessions
|
| | | | |
| 20.00 | | | Official dinner (upon registration)
|